238 related articles for article (PubMed ID: 21168678)
1. Copeptin in relation to New York Heart Association class in heart transplant recipients and kidney transplant recipients.
Malyszko J; Przybylowski P; Koc-Zorawska E; Iaina-Levin N; Sadowski J; Mysliwiec M; Malyszko JS
Transplant Proc; 2010 Dec; 42(10):4259-62. PubMed ID: 21168678
[TBL] [Abstract][Full Text] [Related]
2. Copeptin in heart transplant recipients depends on kidney function and intraventricular septal thickness.
Przybylowski P; Malyszko J; Malyszko JS
Transplant Proc; 2010 Jun; 42(5):1808-11. PubMed ID: 20620528
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of chronic kidney disease in orthotopic heart transplant recipients and kidney allograft recipients using the new Chronic Kidney Disease Epidemiology Collaboration formula.
Malyszko J; Przybylowski P; Malyszko JS; Iaina-Levin N; Sadowski J; Mysliwiec M
Transplant Proc; 2010 Dec; 42(10):4251-4. PubMed ID: 21168676
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-related apoptosis-inducing ligand is a marker of kidney function and inflammation in heart and kidney transplant recipients.
Malyszko J; Przybylowski P; Malyszko J; Koc-Zorawska E; Mysliwiec M
Transplant Proc; 2011 Jun; 43(5):1877-80. PubMed ID: 21693293
[TBL] [Abstract][Full Text] [Related]
5. Vascular adhesion protein-1, a novel molecule, in kidney and heart allograft recipients.
Koc-Zorawska E; Przybylowski P; Malyszko JS; Mysliwiec M; Malyszko J
Transplant Proc; 2013 Jun; 45(5):2009-12. PubMed ID: 23769096
[TBL] [Abstract][Full Text] [Related]
6. Soluble tumor necrosis factor-like weak inducer of apoptosis plasma levels as a novel biomarker of endothelial function in prevalent orthotopic heart transplant recipients.
Przybylowski P; Malyszko JS; Malyszko J
Transplant Proc; 2011 Jun; 43(5):1900-3. PubMed ID: 21693297
[TBL] [Abstract][Full Text] [Related]
7. Blood pressure control in orthotopic heart transplant and kidney allograft recipients is far from satisfactory.
Przybylowski P; Malyszko J; Malyszko JS; Kobus G; Sadowski J; Mysliwiec M
Transplant Proc; 2010 Dec; 42(10):4263-6. PubMed ID: 21168679
[TBL] [Abstract][Full Text] [Related]
8. Serum renalase depends on kidney function but not on blood pressure in heart transplant recipients.
Przybylowski P; Malyszko J; Kozlowska S; Malyszko J; Koc-Zorawska E; Mysliwiec M
Transplant Proc; 2011 Dec; 43(10):3888-91. PubMed ID: 22172866
[TBL] [Abstract][Full Text] [Related]
9. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients.
Meijer E; Bakker SJ; de Jong PE; Homan van der Heide JJ; van Son WJ; Struck J; Lems SP; Gansevoort RT
Transplantation; 2009 Aug; 88(4):561-7. PubMed ID: 19696640
[TBL] [Abstract][Full Text] [Related]
10. Copeptin and its relation to arteriovenous fistula (AVF) type and NYHA class in hemodialysis patients.
Malyszko J; Levin-Iaina N; Malyszko JS; Kozminski P; Koc-Zorawska E; Mysliwiec M
Ren Fail; 2011; 33(10):929-34. PubMed ID: 22013928
[TBL] [Abstract][Full Text] [Related]
11. Serum midkine is related to NYHA class and cystatin C in heart transplant recipients.
Przybylowski P; Malyszko J; Malyszko JS
Transplant Proc; 2010 Nov; 42(9):3704-7. PubMed ID: 21094842
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of chronic kidney disease is extremely high in heart transplant recipients.
Przybylowski P; Malyszko J; Malyszko JS
Transplant Proc; 2009 Oct; 41(8):3239-41. PubMed ID: 19857720
[TBL] [Abstract][Full Text] [Related]
13. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
[TBL] [Abstract][Full Text] [Related]
14. Predictors of kidney dysfunction in heart transplant recipients.
Przybylowski P; Malyszko J; Malyszko JS
Transplant Proc; 2009 Oct; 41(8):3235-8. PubMed ID: 19857719
[TBL] [Abstract][Full Text] [Related]
15. Anemia in heart and kidney allograft recipients: is there a role for hepcidin?
Przybylowski P; Malyszko J; Malyszko JS; Koc-Zorawska E; Sadowski J; Mysliwiec M
Transplant Proc; 2010 Dec; 42(10):4255-8. PubMed ID: 21168677
[TBL] [Abstract][Full Text] [Related]
16. The natural history of renal function following orthotopic heart transplant.
Al Aly Z; Abbas S; Moore E; Diallo O; Hauptman PJ; Bastani B
Clin Transplant; 2005 Oct; 19(5):683-9. PubMed ID: 16146562
[TBL] [Abstract][Full Text] [Related]
17. Hepcidin, an acute-phase protein and a marker of inflammation in kidney transplant recipients with and without coronary artery disease.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Transplant Proc; 2006 Nov; 38(9):2895-8. PubMed ID: 17112858
[TBL] [Abstract][Full Text] [Related]
18. Renalase, a novel regulator of blood pressure, is predicted by kidney function in renal transplant recipients.
Malyszko J; Zbroch E; Malyszko JS; Koc-Zorawska E; Mysliwiec M
Transplant Proc; 2011 Oct; 43(8):3004-7. PubMed ID: 21996211
[TBL] [Abstract][Full Text] [Related]
19. Anemia is a predictor of outcome in heart transplant recipients.
Przybylowski P; Malyszko J; Malyszko J
Transplant Proc; 2009 Oct; 41(8):3228-31. PubMed ID: 19857717
[TBL] [Abstract][Full Text] [Related]
20. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Am J Hematol; 2006 Nov; 81(11):832-7. PubMed ID: 16929540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
